Economic rewarding of smoking cessation-facilitating drugs – a comparison of over-the-counter and prescribed nicotine replacement therapy

Bibliography

• CREALEY GE, MCELNAY JC, MAGUIRE TA, O'NEILL C: Costs and effects associated with a community pharmacy-based smoking-cessation programme Pharmacoeconomics (1998) 14(3):323–333.
   Google Scholar
• CROGHAN IT, OFFORD KP,EVANS RW et al: Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience. Mayo Clin. Proc. (1997) 72(10):917–924.
   PubMedGoogle Scholar
• CROMWELL J, BARTOSCH WJ, FIORE M et al.: Cost-effectiveness of the clinical practice recommendations in the AHCPR Guideline for smoking cessation. JAMA (1997) 278(21):1759–1766.
   PubMed Web of Science ®Google Scholar
• CURRY SJ, GROTHAUS LC,MCAFEE T, PABINIAK CH: Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl. J. Med. (1998) 339(10):673–679.
   PubMed Web of Science ®Google Scholar
• DAUGHTON D, SUSMAN J,SITORIUS M et al: Transdermal nicotine therapy and primary care. Importance of counselling, demographic, and participant selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation Trial Group. Arch. Fain. Med. (1998) 7(5):425–430.
   Google Scholar
• DAVIDSON M, EPSTEIN M, BURT R et al.: Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. Arch. Fam. Med. (1998) 7(6):569–574.
   PubMedGoogle Scholar
• DUNLOP H: Bupropion (Zyban® sustained-release tablets): update. CMA1(2000) 162(1):106–107.
   Google Scholar
• FIORE MC, BAILEY WC, COHEN SCet al.: Smoking cessation: Clinical Practice Guideline No. 18. (1996) Agency for Health Care Policy and Research, Rockville, MD, USA.
   Google Scholar
• FISCELLA K, FRANKS P: Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counselling. JAMA (1996) 275(16):1247–1251.
   PubMedGoogle Scholar
• GODFREY CH, FOWLER G: Pharmacoeconomic considerations in the management of smoking cessation. Drugs (2002) 62 (Suppl. 2):63–70.
   Google Scholar
• HAYS JT, CROGHAN IT,SCHROEDER DR et al: Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. Am. .1. Public Health (1999) 89(11):1701–1707.
   Google Scholar
• HUGHES JR, GOLDSTEIN MG, HURT RD, SHIFFMAN S: Recent advances in the pharmacotherapy of smoking. JAMA (1999) 281(1):72–76.
   PubMed Web of Science ®Google Scholar
• HUGHES JR, SHIFFMAN S, CALLAS P, ZHANG J: A meta-analysis of the efficacy of over-the-counter nicotine replacement Tob. Control (2003) 12(1):21–27.
   Google Scholar
• •This article represents the only available published meta-analysis concerning the efficacy of OTC NRT providing important data on this field.
   Google Scholar
• HUGHES JR: Four beliefs that may impede progress in the treatment of smoking. Tob. Control (1999) 8(3):323–326.
   PubMedGoogle Scholar
• JOLICOEUR DG, RICHTER KP, AHLUWALIA JS, MOSIER MC, RESNICOW K: Smoking cessation, smoking reduction, and delayed quitting among smokers given nicotine patches and a self-help pamphlet. Subst. Abus. (2003) 24(2):101–106.
   PubMedGoogle Scholar
• KEELER TE, HU TW, KEITH A et al: The benefits of switching smoking cessation drugs to over-the-counter status.Health Econ. (2002) 11(5):389–402.
   PubMedGoogle Scholar
• LANCASTER T, STEAD L, SILAGY CH, SOWDEN A: Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. Br. Med. .1 (2000) 321(7257):355–358.
   Google Scholar
• LAWRENCE WE SMITH SS, BAKER TB, FIORE MC: Does over-the-counter nicotine replacement therapy improve smokers' life expectancy? Tob. Control (1998) 7(4):364–368.
   Google Scholar
• LIGHTWOOD M, GLANTZ S: Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation (1997) 96(01089–1096.
   PubMed Web of Science ®Google Scholar
• MCGHAN WE SMITH MD: Pharmacoeconomic analysis of smoking-cessation interventions. Am. J. Health. Syst. Pharm. (1996) 53(1):45–52.
   PubMedGoogle Scholar
• OSTER G, DELEA TE, HUSE DM, REGAN MM, COLDITZ GA: The benefits and risks of over-the-counter availability of nicotine polacrilex ('nicotine gum'). Med. Care (1996) 34(5):389–402.
   PubMedGoogle Scholar
• PIERCE JP, GILPIN EA: Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA (2002) 288(10):1260–1264.
   PubMed Web of Science ®Google Scholar
• RANSON MK, JHA P, CHALOUPKA FJ, NGUYEN SN: Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies. Nicotine Tob. Res. (2002) 4(3):311–319.
   PubMedGoogle Scholar
• SHIFFMAN S, GORSLINE J, GORODETZKY CW: Efficacy of over-the-counter nicotine patch. Nicotine Tob. Res. (2002) 4(4):477–483.
   PubMedGoogle Scholar
• SHIFFMAN S, ROLF CN, HELLEBUSCH SJ et al.: Real-world efficacy of prescription and over-the-counter nicotine replacement.Addiction (2002) 97(5):505–516.
   PubMedGoogle Scholar
• SHIFFMAN S, GITCHELL J,PINNEY JM et al.: Public health benefit of over-the-counter nicotine medications. Tob. Control (1997) 6(4):306–310.
   Google Scholar
• SCHAUFFLER HH, MCMENAMIN S, OLSON K, BOYCE-SMITH G, RIDE OUT JA, KAMIL J: Variations in treatment benefits influence smoking
   Google Scholar
• ••cessation: results of a randomised controlled trial. Tob. Control (2001) 10(2):175–180.
   Google Scholar
• SILAGY C, LANCASTER T, STEAD L et al.: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev (2003) 3:CD000146.
   Google Scholar
• ••This article represents the most recentstandardised review on NRT providing baseline data for further research as well as guidelines in this field.
   Google Scholar
• SONG F, RAFTERY J, AVEYARD P et al: Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis Med. Decis. Making (2002) 22(5 Suppl.):S26–S37.
   Google Scholar
• STAPLETON JA, LOWIN A, RUSSELL MA: Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet (1999) 354(9174):210–215.
   PubMedGoogle Scholar
• THE TOBACCO USE ANDDEPENDENCE CLINICAL PRACTICEGUIDELINE PANEL, STAFF, AND CONSORTIUM REPRESENTATIVES: A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service Report. JA/VIA (2000) 283(24):3244–3254.
   Google Scholar
• THE WORLD HEALTH REPORT 2002. Reducing Risks, Promoting Healthy Life. World Health Organization: Geneva, Switzerland (2002).
   Google Scholar
• THORNDIKE AN, BIENER L, RIGOTTI NA: Effect on smoking cessation of switching nicotine replacement therapy to over-the-counter status. Jim. .1 Public Health (2002) 92(3):437–442.
   Google Scholar
• WARNER KE: Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. Pharmacoeconomics (1997) 11(6):538–549.
   Google Scholar
• WASLEY MA, MCNAGNY SE, PHILLIPS VL, AHLUWALIA JS: The cost-effectiveness of the nicotinetransdermal patch for smoking cessation. Prey Med. (1997) 26(2):264–270.
   PubMedGoogle Scholar
• WEST R, MCNEILL A, RAW M: Smokingcessation guidelines for health professionals: an update. Thorax (2000) 55(12):987–999.
   PubMed Web of Science ®Google Scholar
• http://www.surgeongeneral.gov/tobacco/ CDC: Tobacco Cessation Guideline. Accessed: November 03, 2003.
   Google Scholar
• http://gateway.ovid.com/ OVID.Accessed: January 26, 2004.
   Google Scholar